CLOs on the Move

Rx Savings Solutions

www.rxsavingssolutions.com

 
Revolutionizing healthcare by educating, motivating and empowering consumers and payers of prescription drugs to save money.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details
Brett Bogan
Corporate Counsel Profile

Similar Companies

Valley Counseling Group

Valley Counseling Group is a Bethlehem, PA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Babson Diagnostics

Babson Diagnostics is bringing medically-accurate blood testing to the pharmacy, and empowering people to take charge of their health by reimagining the entire blood testing process from ordering, collection, handling, analyzing, and reporting of results, making it less invasive and more convenient, accessible, and patient-centered.

eviti

eviti is a Philadelphia, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Geneva Centre for Autism

Geneva Centre for Autism is a Toronto, ON-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Relmada

Relmada Therapeutics (OTCQB: RLMD) is a clinical-stage, publicly traded specialty pharmaceutical company developing novel versions of proven drug products together with new chemical entities that potentially address areas of high unmet medical need in the treatment of chronic pain. Relmada has a diversified portfolio of four lead products at various stages of development including d-Methadone (REL-1017) its N-methyl-D-aspartate (NMDA) receptor antagonist for neuropathic pain; topical mepivacaine (REL-1021), its orphan drug designated topical formulation of the local anesthetic mepivacaine; oral buprenorphine (REL-1028) its oral dosage form of the opioid analgesic buprenorphine; and LevoCap ER (REL-1015), its abuse resistant, sustained release dosage form of the opioid analgesic levorphanol. Relmada`s product development efforts are guided by the internationally recognized scientific expertise of our research team. Relmada`s approach is expected to reduce clinical development risks and costs while potentially delivering valuable products in areas of high unmet medical needs.